FOLFIRINOX Improves PFS Compared with Gemcitabine in Patients with Locally Advanced Pancreatic Carcinoma By Ogkologos - May 26, 2025 629 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PRODIGE 29-UCGI 26 (NEOPAN) study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR One Million Masks Donated! But GreaterGood Will Continue to Help Where... October 5, 2020 Advanced MRI could help to differentiate aggressive and slower growing prostate... February 14, 2022 ΚΑΡΚΙΝΟΣ ΣΤΟΜΑΧΟΥ February 7, 2019 Making the most of your ‘eureka’ moment: getting from the science... September 22, 2021 Load more HOT NEWS Outcome of EMA Assessment on Use of Lutetium (177Lu) in Treatment... FDA Grants Accelerated Approval to Selpercatinib for Paediatric Patients Two Years... FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma COVID-19 vaccine and cancer – latest updates
